Table 3.

Association of variables with hazard ratios for OS in univariate analysis.

Factor	HR	95%CI	p-Value
Age at AML diagnosis (per year increase)	1.047	1.030–1.065	<0.0001
ECOG performance status (2–4 versus 0–1)	2.608	1.695–4.014	<0.0001
Cytopenias 6–36 months before AML diagnosis
Anemia	1.772	1.156–2.717	0.008
Macrocytic anemia	6.281	2.478–15.913	0.0001
Thrombocytopenia	3.186	1.543–6.464	0.002
Macrocytic anemia or thrombocytopenia	4.098	2.182–7.698	<0.0001
Leukopenia	0.786	0.486–1.270	0.32
Counts at AML diagnosis
Hematocrit	1.025	0.988–1.064	0.18
Platelet count	0.998	0.995–1.001	0.22
White blood count	1.002	0.998–1.006	0.26
Peripheral blood blast percentage	0.999	0.992–1.006	0.77
Bone marrow blast percentage	0.997	0.988–1.006	0.52
Bone marrow cellularity	0.999	0.990–1.007	0.77
AML karyotype risk group (versus intermediate)
Favorable	0.235	0.085–0.650	0.005
Adverse	2.016	1.283–3.170	0.002
AML with myelodysplasia-related changes	2.43	1.600–3.691	<0.0001
NPM1/FLT3 mutation status
FLT3 ITD mutation	1.042	0.710–2.965	0.31
NPM1 mutation	1.253	0.643–2.442	0.51
NPM1 mutated/FLT3 wild-type	1.552	0.713–3.380	0.27
Type of AML therapy (versus supportive care)
Low-intensity agents	0.156	0.079–0.308	<0.0001
Induction chemotherapy	0.048	0.025–0.092	<0.0001
Treatment with stem cell transplant	0.384	0.239–0.617	<0.0001